Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

Fig. 1

Distribution of (a) TGR0 and (b) percentage change in SLD among patients during the pre-treatment period. a Distribution of TGR0 among patients during the pre-treatment period according to RECIST v1.0 classification. Individual data points represent the TGR0 in individual patients (ITT population), according to their classification by RECIST v1.0. Boxes represent median and interquartile range (Q1–Q3), whiskers represent the minimum observation still within 1.5 IQR of lower quartile (Q1), and the maximum observation still within 1.5 IQR of the upper quartile (Q3). Median (IQR) TGR0: 2.1%/month (0.2; 6.1) (lanreotide 120 mg); 2.7%/month (0.15; 6.8) (placebo). b Percentage changes in SLD during the pre-treatment period among individual patients (ITT population). Data are sorted from high percentage change in SLD to low percentage change in SLD over the pre-treatment period. A patient with a change in SLD less than 20% had PD due to the presence of new lesions. Lanreotide 120 mg, n = 100; placebo, n = 100. ITT, intention-to-treat; IQR; interquartile range; PD, progressive disease; RECIST, response evaluation criteria in solid tumors; SLD, sum of longest diameters; TGR0, pre-treatment tumor growth rate

Back to article page
\